Syntex (u.s.a.) Inc.

Agouron Pharmaceuticals, Inc.

Other

Roche Palo Alto LLC

Xyntex (u.s.a) Inc.

Keith Adrian Walker

Michael Marx

Jian Jeffrey Chen

Arlindo Lucas Castelhano

Jeffrey Allen Campbell

Chris Allen Broka

Michael J Melnick

Robert Than Hendricks

Gregory R Martinez

David Bernard Smith

Brian H Vickery

Denis John Kertesz

David Bruce Repke

Richard E Jones

Roger L Whiting

Helen Y Wu

John J Bruno

Walter Kurz

Duane W Hallesy

Counde O'Yang

Timothy D Owens

Sharada Shenvi Labadie

Todd Richard Elworthy

Nancy Elisabeth Krauss

Michael G Roepel

Taraneh Mirzadegan

Pamela M Burton

Owen W Gooding

Steven Sethofer

Counde O-Yang

Philip Jay Teitelbaum

Gregory Ricardo Martinez

Stefan Howard Unger

Shu Hai Zhao

David C Swinney

Tara Mirzadegan

Craig W Laughton

Philip J Teitelbaum

Compounds of the formula I: or pharmaceutically acceptable salts thereof wherein m, n, X, Ar, R, R, R, Rand Rare as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Benzimidazolone and dihydroindolone derivatives and uses thereof

This invention relates to anti-inflammatory and analgesic compounds, especially to certain p-(sulfonyl)phenyl amino derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

P-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents

A baseball swing training apparatus including that enables a batter to determine whether his swing followed the proper principles for hitting or batting. Oriented for use by both right-handed and left-handed batters it is intended to teach batters how their wrists should react in order to most effectively hit a ball. This generally baseball bat shaped apparatus includes a swing indicator disposed inside the barrel, which impacts one of four impact points producing an audible response when a swing is performed correctly. An incorrect swing produces no audible response.

Baseball swing training apparatus

This invention relates to compounds which are generally EPreceptor agonists and which are represented by Formula I:wherein A is a &#x2014;CH&#x2014;CH&#x2014;, or &#x2014;CH&#x2550;CH&#x2014;; B is absent, an aryl, or heteroaryl group; Ris alkyl, alkenyl, alkynyl, cycloalkylalkyl, heterocyclylalkyl, aryl, arylalkyl or heteroaryl, when B is aryl or heteroaryl and R, R, Rand Rare not simultaneously hydrogen, or Ris heterocyclylalkyl, aryl, or heteroaryl when B is absent and R, R, Rand Rare simultaneously hydrogen; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

8-aza-11-deoxy prostaglandin analogues

This invention relates to sulfamides of formula (I) ##STR1## that are inhibitors of metalloproteases, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

Sulfamide-metalloprotease inhibitors

The present invention relates to novel benzocycloalkylazolethione compounds which are dopamine .beta.-hydroxylase inhibitors in which the benzocycloalkyl portion of the compound is selected from indanyl, 1,2,3,4-tetrahydronaphthalenyl and 6,7,8,9-tetrahydro-5H-benzocycloheptenyl (in which the benzo is optionally substituted with one to three substituents) and the azolethione portion of the compound is selected from 2-thioxo-2,3-dihydro-1H-imidazol-3-yl, 5-thioxo-4,5-dihydro-1H-�1,2,4!triazol-4-yl and 5-thioxo-4,5-dihydro-1H-�1,2,4!triazol-1-yl (each optionally substituted with one to three substituents); and the prodrugs, pharmaceutically acceptable salts, individual isomers and mixtures of isomers and the methods of using and preparing such benzocycloalkylazolethione compounds.

Benzocycloalkylazolethione derivatives and processes for preparing the

The present invention relates to novel benzocycloalkylazolethione compounds which are dopamine .beta.-hydroxylase inhibitors in which the benzocycloalkyl portion of the compound is selected from indanyl, 1,2,3,4-tetrahydronaphthalenyl and 6,7,8,9-tetrahydro-5H-benzocycloheptenyl (in which the benzo is optionally substituted with one to three substituents) and the azolethione portion of the compound is selected from 2-thioxo-2,3-dihydro-1H-imidazol-3-yl, 5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-4-yl and 5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-1-yl (each optionally substituted with one to three substituents); and the prodrugs, pharmaceutically acceptable salts, individual isomers and mixtures of isomers and the methods of using and preparing such benzocycloalkylazolethione compounds.

Benzocycloalkylazolethione derivatives

Compounds of general formula (I) ##STR1## wherein R.sup.1 is (CH.sub.2).sub.n ((CHNR.sup.7 R.sup.8).sub.m C(O)R.sup.9 ; n=1-3; and m=0 or 1;

4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl

Nucleosides compounds of Formula I: ##STR1## wherein B is a purine or a pyrimidine;

4'-substituted nucleosides

Compounds of formula (I): ##STR1## wherein n is 2 or 3;

1,3-Dioxolane derivatives as cholesterol-lowering agents

Compounds useful in treating or preventing gastrointestinal ulcers and in treating cardiovascular disorders such as thrombosis, hypertension and atherosclerosis are depicted in formulas (1), (2) and (3): ##STR1## wherein: A is --C.tbd.C--, trans --HC.dbd.CH--, trans --CH.dbd.CHCH.sub.2 -- or --CH.sub.2 CH.sub.2 --;

Novel 6-alkyl and 6.8-dialkylbicyclo(4.2.0)octane derivatives

A process for preparing compounds represented by the formula ##STR1## wherein: X is hydrogen or lower alkoxy;

Novel processes for the synthesis of certain bicyclo(4.2.0)octane

The invention concerns a method of inhibiting both thromboxane synthetase and cyclic-AMP phosphodiesterase in a mammal having a disease characterized by elevated thromboxane levels or an imbalance of prostacyclin/thromboxane levels with a compound of the formula: ##STR1## or a pharmaceutically acceptable acid addition salt or ester thereof, wherein:

Carbostyril derivatives as combined thromboxane synthetase and

Growing community of inventors

Los Altos Hills, CA, United States of America

Keith Adrian Walker